US patents related to the Life Sciences sector in Australia and New Zealand and granted in 2015
Compiled by Stuart Roberts, Senior Analyst, stuart@ndfresearch.com, +61 447 247 909 (3 October 2017)
The US Patent Office issues new patents every Tuesday. Australian assignees generally get two or three healthcare and biotech-related patents a week while New Zealand assignees get one every three or four weeks.
The US Patent Office issues new patents every Tuesday. Australian assignees generally get two or three healthcare and biotech-related patents a week while New Zealand assignees get one every three or four weeks.
Australian grants
Here are the 140 US patents relevant to Australia's Life Sciences sector that were granted in 2015, for an issuance rate of 2.7 per week:
- US Patent 9,221,799, Anti-cancer agents, Walter and Eliza Hall Institute, 29 December 2015
- US Patent 9,220,928, Plant extracts from Acronychia species and their use, EcoBiotics, 29 December 2015
- US Patent 9,220,806, Biocompatible material and uses thereof, University of Sydney, 29 December 2015
- US Patent 9,220,724, MicroRNA-based approach to treating malignant pleural mesothelioma, Asbestos Diseases Research Institute, 29 December 2015
- US Patent 9,220,678, Coating method, University of Queensland, 29 December 2015
- US Patent 9,211,331, Mineral based composition and methods of use, Tuffrock, 15 December 2015
- US Patent 9,211,329, Method of treating inflammatory bowel disease, CSL Ltd (ASX: CSL), 15 December 2015
- US Patent 9,211,237, Film foaming hydroalcoholic foam, Stiefel Research Australia, 15 December 2015
- US Patent 9,206,171, 6-{2 -[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzi- soxazole bis-dihydrogenphosphate salt (1:2), Biota, 8 December 2015
- US Patent 9,205,121, Echinacea formulation, Integria Healthcare, 8 December 2015
- US Patent 9,200,020, 6-oxopurine phosphoribosyltransferase inhibitors, University of Queensland with the Institute of Organic Chemistry and Biochemistry (Czechia), 1 December 2015
- US Patent 9,199,976, Haematopoietic-prostaglandin D2 synthase inhibitors, University of Queensland, 1 December 2015
- US Patent 9,193,716, S1P receptors modulators and their use thereof, Akaal Pharma, 24 November 2015
- US Patent 9,193,793, Antibodies against G-CSFR and uses thereof, CSL Ltd, 24 November 2015
- US Patent 9,186,404, Brain, spinal and nerve injury treatment, Eustralis Pharmaceuticals, 17 November 2015
- US Patent 9,186,321, Oral spray formulations and methods for administration of sildenafil, Suda Ltd (ASX: SUD), 17 November 2015
- US Patent 9,181,320, Peptides for generating an antibody selectively binding to a non-ATP-binding P2X7 receptor but not to an ATP-binding P2X7 receptor, Biosceptre International, 10 November 2015
- US Patent 9,180,194, Method and composition for transdermal drug delivery, Acrux (ASX: ACR), 10 November 2015
- US Patent 9,175,279, Method of purifying factor VII and/or factor VIIa, CSL Ltd (ASX: CSL), 3 November 2015
- US Patent 9,174,982, Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, Walter and Eliza Hall Institute with AbbVie (US) and Genentech (US), 3 November 2015
- US Patent 9,173,911, Method for producing vegetable cell sap concentrate and means for the production thereof, Solagran with SibEX (Russia), 3 November 2015
- US Patent 9,173,866, Compositions and products containing R-equol, and methods for their making, Sanitarium with Cincinnati Children's Hospital (US), 3 November 2015
- US Patent 9,169,495, Targeted gene delivery to non-phagocytic mammalian cells via bacterially derived intact minicells, EnGeneIC, 27 October 2015
- US Patent 9,169,329, Antibodies directed to the receptor tyrosine kinase c-Met, Monash University with the Ludwig Institute for Cancer Research (US), 27 October 2015
- US Patent 9,169,211, 8-hydroxy quinoline derivatives, Prana Biotechnology (ASX: PBT), 27 October 2015
- US Patent 9,168,302, Reduction of side effects from aromatase inhibitors used for treating breast cancer, Chavah Pty Ltd , 27 October 2015
- US Patent 9,168,216, Carrier comprising one or more di and/or mono-(electron transfer agent) phosphate derivatives or complexes thereof, Phosphagenics (ASX: POH), 27 October 2015
- US Patent 9,163,081, Antibody recognizing C-domain of midkine, Cellmid (ASX: CDY), 20 October 2015
- US Patent 9,163,029, Substituted imidazo[1,2-a]pyrrolo[1,2-d]pyrazines for treating respiratory syncytial virus infections, Biota, 20 October 2015
- US Patent 9,163,018, Method of treatment of age-related macular degeneration (AMD), Prana Biotechnology (ASX: PBT), 20 October 2015
- US Patent 9,162,985, Salts and solvates of a tetrahydroisoquinoline derivative, Spinifex Pharmaceuticals, 20 October 2015
- US Patent 9,161,923, Composition for prevention and treatment of contact lens papillary conjunctivitis and allergic eye disease, Brian Holden Vision Institute, 20 October 2015
- US Patent 9,161,562, Natural sweetener, Horizon Science Pty Ltd (David Kannar and Barry Kitchen), 20 October 2015
- US Patent 9,157,054, Device and method for preparing microparticles, University of Queensland, 13 October 2015
- US Patent 9,156,916, Modulation of T helper cell-mediated immune responses, University of Sydney withNorthern Sydney and Central Coast Area Health Service, 13 October 2015
- US Patent 9,156,855, Regulation of nitric oxide release and biofilm development, University of New South Wales with University of Wollongong, 13 October 2015
- US Patent 9,155,760, Method of prophylaxis of bacterial vaginosis, Starpharma, 13 October 2015
- US Patent 9,150,621, Mutant bacterial glycoproteins and uses thereof, University of Queensland, 6 October 2015
- US Patent 9,150,619, Method of elicting or inducing an immune response, CSL Ltd (ASX: CSL) with University of Melbourne, 6 October 2015
- US Patent 9,149,452, Methods and compositions for promoting the neurological development of an infant, Women's & Children's Health Research Institute, 6 October 2015
- US Patent 9,145,375, Quinazolinone compounds, Prana Biotechnology (ASX: PBT), 29 September 2015
- US Patent 9,139,879, TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease, Florey Institute of Neuroscience and Mental Health, 22 September 2015
- US Patent 9,134,311, Methods and compositions for treating and preventing malaria using an invasion ligand directed to a protease-resistant receptor, Walter and Eliza Hall Institute, 15 September 2015
- US Patent 9,133,188, Methods for preparing naphthyridines, Bionomics (ASX: BNO), 15 September 2015
- US Patent 9,131,681, Particles comprising a releasable dopant therein, Australian Nuclear Science & Technology Organisation, 15 September 2015
- US Patent 9,127,130, Polylysine dendrimer contrast agent, Starpharma (ASX: SPL) with Baker IDI Heart and Diabetes Institute, 8 September 2015
- US Patent 9,127,057, Anti-IL-23 heterodimer specific antibodies, Teva Pharmaceuticals Australia, 8 September 2015
- US Patent 9,125,943, Reconstituted HDL formulation, CSL Ltd (ASX: CSL), 8 September 2015
- US Patent 9,125,853, Treatment or prevention of infection, Oral Health CRC, 8 September 2015
- US Patent 9,122,778, Methods of treating diseases, Biotempus, 1 September 2015
- US Patent 9,120,775, Viral polymerase inhibitors, Biota, 1 September 2015
- US Patent 9,119,833, Administration of relaxin to treat nephrogenic diseases of water imbalance involving acquaporin-4, University of Melbourne with University of Florida, 1 September 2015
- US Patent 9,119,818, Use of angiogenin or angiogenin agonists for treating diseases and disorders, Murray Goulburn Co-Operative with Agriculture Victoria Services, 1 September 2015
- US Patent 9,119,805, Therapy and prevention of problem drinking, University of Sydney, 1 September 2015
- US Patent 9,119,394, Anti-microbial polymers and their compositions, Recce (ASX: RCE), 1 September 2015
- US Patent 9,115,363, Gene expression and eradication system in Helicobacter pylori, Ondek, 25 August 2015
- US Patent 9,110,061, Use of amino acid sequences from Mycobacterium tuberculosis or corresponding nucleic acids for diagnosis and prevention of tubercular infection, diagnostic kit and vaccine therefrom, Cellestis, 18 August 2015
- US Patent 9,109,040, Treatment and prevention of malaria, Walter and Eliza Hall Institute, 18 August 2015
- US Patent 9,107,811, Composition for treating skin lesions, Sci-Chem International Pty Ltd, 18 August 2015
- US Patent 9,101,732, Drug-delivery accessory for an implantable medical device, Cochlear (ASX: COH), 11 August 2015
- US Patent 9,101,650, Treatment of bone marrow edema (oedema) with polysulfated polysaccharides, Paradigm Biopharma (ASX: PAR), 11 August 2015
- US Patent 9,095,587, Methods and compositions for improved nerve conduction velocity, Spinifex Pharmaceuticals, 4 August 2015
- US Patent 9,095,524, Customized compositions and uses thereof, Bond University, 4 August 2015
- US Patent 9,095,519, Dosage form containing two or more active pharmaceutical ingredients in different physical forms, Alphapharm Pty Ltd, 4 August 2015
- US Patent 9,090,706, Fibronectin: growth factor chimeras, Queensland University of Technology, 28 July 2015
- US Patent 9,089,508, Method of transfection and compositions therefor, University of Melbourne, 28 July 2015
- US Patent 9,085,770, Delivery of dsRNA to arthropods, Commonwealth Scientific and Industrial Research Organisation, 21 July 2015
- US Patent 9,085,628, Antibody molecule for human GM-CSF receptor alpha, CSL Ltd (ASX: CSL) with Medimmune (US), 21 July 2015
- US Patent 9,084,827, Biodegradable polyurethane/urea compositions, Polynovo (ASX: PNV), 21 July 2015
- US Patent 9,084,770, Modulation of insulin like growth factor I receptor expression in cancer, Antisense Therapeutics (ASX: ANP), 21 July 2015
- US Patent 9,079,967, Modified chaperonin 10, Invion (ASX: IVX), 14 July 2015
- US Patent 9,079,950, Modified Hepatitis C virus proteins, Burnet Institute, 14 July 2015
- US Patent 9,078,845, Anti-microbial agent, Kayban Pty Ltd, 14 July 2015
- US Patent 9,078,816, Buccal, polar and non-polar spray containing ondansetron, Suda Ltd (ASX: SUD), 14 July 2015
- US Patent 9,078,810, Transdermal delivery system, Acrux (ASX: ACR), 14 July 2015
- US Patent 9,073,997, Growth factor antagonists for organ transplant alloimmunity and arteriosclerosis, Opthea (ASX: OPT), 7 July 2015
- US Patent 9,066,982, Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells, EnGeneIC, 30 June 2015
- US Patent 9,066,919, Hyaluronan as a chemo-sensitizer in the treatment of cancer, Alchemia (ASX: ACL), 30 June 2015
- US Patent 9,066,526, Allergy treatment using acid treated aqueous whey protein extract, Dairy Australia, 30 June 2015
- US Patent 9,063,155, Immunotherapeutic method of treating neoplastic conditions, Medvet Science Pty Ltd, 23 June 2015
- US Patent 9,062,288, Therapeutic methods using adipose tissue-derived cell suspensions comprising adipocytes, Regeneus (ASX: RGS), 23 June 2015
- US Patent 9,062,118, J-superfamily conotoxin peptides, University of Queensland with University of Utah (US) and the Max Planck Society (Germany), 23 June 2015
- US Patent 9,062,013, Positive allosteric modulators of the alpha.7 nicotinic acetylcholine receptor and uses thereof, Bionomics (ASX: BNO), 23 June 2015
- US Patent 9,062,013, Chimeric relaxin polypeptides comprising an A and B chain derived from different relaxin family peptides, Florey Institute of Neuroscience and Mental Health, 16 June 2015
- US Patent 9,051,551, Methods and compositions for increasing sensitivity to tyrosine kinase inhibitors, University of Western Australia, 9 June 2015
- US Patent 9,051,369, Avian cytokines and genetic sequences encoding same, Commonwealth Scientific and Industrial Research Organisation, 9 June 2015
- US Patent 9,045,475, Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, Walter and Eliza Hall Institute with AbbVie (US) and Genentech (US), 2 June 2015
- US Patent 9,045,452, Antimicrobial and radioprotective compounds, BioDiem, 2 June 2015
- US Patent 9,044,489, Medicinal compositions containing honey, Medihoney Pty Ltd, 2 June 2015
- US Patent 9,040,503, Medicinal carbohydrates for treatment of respiratory conditions, Aus Bio Ltd, 26 May 2015
- US Patent 9,035,028, Temperature sensitive conjugate compositions, Baker IDI Heart and Diabetes Institute with Emory University (US), 19 May 2015
- US Patent 9,034,381, Process to control particle size, Alphapharm Pty Ltd, 19 May 2015
- US Patent 9,034,378, Biodegradable polyurethane and polyurethane ureas, PolyNovo (ASX: PNV), 19 May 2015
- US Patent 9,023,892, Antimicrobial compounds, Ramiz Boulos, 5 May 2015
- US Patent 9,023,863, Fatty acid pharmaceutical foam, Stiefel Research Australia, 5 May 2015
- US Patent 9,023,799, Method to reduce loss of cardiac function following ischemia/reperfusion, Cellmid (ASX: CDY), 5 May 2015
- US Patent 9,018,247, Compositions and products containing S-equol, and methods for their making, Sanitarium with Cincinnati Children's Hospital (US), 28 April 2015
- US Patent 9,018,207, Method of treatment or prophylaxis, Spinifex Pharmaceuticals, 28 April 2015
- US Patent 9,018,168, Therapeutic method for treating congestive heart failure, Madeleine Pharmaceuticals, 28 April 2015
- US Patent 9,017,697, Compositions and methods for modulating immune responses, University of Queensland, 28 April 2015
- US Patent 9,017,643, Particles comprising a releasable dopant therein, Australian Nuclear Science & Technology Organisation, 28 April 2015
- US Patent 9,012,461, FAK inhibitors, Cancer Therapeutics CRC Pty Ltd, 21April, 2015
- US Patent 9,011,878, Vaccine strains of Brachyspira hyodysenteriae, Spirogene Pty Ltd, 21 April 2015
- US Patent 9,006,397, FN14 binding proteins and uses thereof, TransBio, 14 April 2015
- US Patent 9,006,284, Combination therapy for treating proliferative diseases, Bionomics (ASX: BNO), 14 April 2015
- US Patent 9,006,200, MicroRNA-based approach to treating malignant pleural mesothelioma, Asbestos Diseases Research Institute, 14 April 2015
- US Patent 8,999,920, Reconstituted high density lipoprotein formulation and production method thereof, CSL Ltd (ASX: CSL), 7 April 2015
- US Patent 8,999,353, Method of eliciting an immune response against pandemic influenza virus, CSL Ltd (ASX: CSL), 7 April 2015
- US Patent 8,993,635, Method of increasing or maintaining the reproductive performance of sows, Pork CRC, 31 March 2015
- US Patent 8,993,520, Method and composition for transdermal drug delivery, Acrux (ASX: ACR), 31 March 2015
- US Patent 8,992,986, Controlled release of biological entities, Australian Nuclear Science & Technology Organisation, 31 March 2015
- US Patent 8,992,982, Formulation of indomethacin, iCeutica, 31 March 2015
- US Patent 8,992,935, Means of controlling infection persistence of Helicobacter pylori , Ondek, 31 March 2015
- US Patent 8,986,700, Immunogenic lipopeptides comprising T-helper and cytotoxic T-lymphocyte (CTL) epitopes, Queensland Institute of Medical Research, 24 March 2015
- US Patent 8,980,914, Therapeutic agent for chronic obstructive pulmonary disease and method for treatment for chronic obstructive pulmonary disease with the same, Mariposa Health, 17 March 2015
- US Patent 8,975,278, 8-hydroxy quinoline derivatives, Prana Biotechnology (ASX: PBT), 10 March 2015
- US Patent 8,975,245, Anaesthetic formulation, Drawbridge Pharmaceuticals, 10 March 2015
- US Patent 8,974,803, Injectable biomaterials, University of Sydney, 10 March 2015
- US Patent 8,968,731, Treatment of uveitis, CSL Ltd (ASX: CSL), 3 March 2015
- US Patent 8,962,830, Protein kinase inhibitors and methods of treatment, Walter and Eliza Hall Institute, 24 February 2015
- US Patent 8,962,801, Neisseria porin proteins, Griffith University, 24 February 2015
- US Patent 8,962,649, Multidose package, course and method of treatment for delivering predetermined multiple doses of a pharmaceutical, iNova Pharmaceuticals, 24 February 2015
- US Patent 8,960,128, Topical anesthetic composition, Animal Ethics Pty Ltd, 24 February 2015
- US Patent 8,957,099, Treatment of ADHD, Gosforth Clinic (Dr Philip Bird), 17 February 2015
- US Patent 8,956,864, Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells, EnGeneIC, 17 February 2015
- US Patent 8,952,157, Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases, AbbVie and Walter and Eliza Hall Institue of Medical Research, 10 February 2015
- US Patent 8,951,543, Nano silver--zinc oxide composition, Polymers CRC, 10 February 2015
- US Patent 8,946,381, Compositions and uses thereof for the treatment of wounds, Phylogica (ASX: PYC) and the McComb Foundation, 3 February 2015
- US Patent 8,946,146, Method for modulating appetite, St Vincent's Hospital Sydney., 3 February 2015
- US Patent 8,945,551, Biopolymer hybrid gel-depot delivery system, Polymers CRC, 3 February 2015
- US Patent 8,940,695, Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy, Opthea (ASX: OPT), 27 January 2015
- US Patent 8,939,932, Inactivation of papillomavirus, Dr Jenny McCloskey, 27 January 2015
- US Patent 8,937,052, Therapeutic protocols using hyaluronan, Alchemia (ASX: ACL), 20 January 2015
- US Patent 8,933,092, Methods and compositions comprising sequential administration opioid receptor agonists, QRXPharma, 13 January 2015
- US Patent 8,933,033, Chaperonin 10 variants, Invion (ASX: IVX), 13 January 2015
- US Patent 8,933,027, Method of treating a disease or condition characterised by aberrant epithelial cell proliferation, Queensland University of Technology, 13 January 2015
- US Patent 8,932,588, Treatment of cancer involving mutated KRAS or BRAF genes, Teva Pharmaceuticals Australia, 13 January 2015
- US Patent 8,927,575, Salts and solvates of a tetrahydroisoquinoline derivative, Spinifex Pharmaceuticals, 6 January 2015
- US Patent 8,927,565, Compositions for veterinary and medical applications, Aus Bio Ltd, 6 January 2015
- US Patent 8,927,503, Modulations of protease activated receptors, University of Queensland, 6 January 2015
New Zealand applications
Here are the 12 US patents relevant to New Zealand's Life Sciences sector that were granted in 2015, for an issuance rate of 0.2 applications per week:
- US Patent 9,212,204, Treatment of Rett Syndrome using glycyl-L-2-methylprolyl-L-glutamic acid, Neuren Pharmaceuticals (ASX: NEU), 15 December 2015
- US Patent 9,198,430, Anti-parasitic composition comprising a macrocyclic lactone and levamisole and method of treatment of parasitic infestation, Bayer New Zealand, 1 December 2015
- US Patent 9,119,851, Cyclic Glycyl-2-Allyl Proline improves cognitive performance in impaired animals, Neuren Pharmaceuticals (ASX: NEU), 1 September 2015
- US Patent 9,102,743, Immunogenic polypeptide isolated from Mycobacterium avium subspecies paratuberculosis and uses thereof, Massey University with Institut Pasteur (France), 11 August 2015
- US Patent 9,101,632, Kinase inhibitors, prodrug forms thereof and their use in therapy, Auckland UniServices (University of Auckland), 11 August 2015
- US Patent 9,095,430, Biomaterials with enhanced properties and devices made therefrom, Southern Lights Ventures, 4 August 2015
- US Patent 9,079,859, Synthetic lethal targeting of glucose transport, Auckland UniServices (University of Auckland) with Stanford University (US) and Ruga Corp (US), 14 July 2015
- US Patent 9,073,916, Prodrug forms of kinase inhibitors and their use in therapy, Auckland UniServices (University of Auckland), 7 July 2015
- US Patent 9,045,505, Nitric oxide donors, University of Otago and Medical Research Council (UK), 2 June 2015
- US Patent 9,040,485, Synthetic analogues of neural regeneration peptides, CuroNZ, 26 May 2015
- US Patent 8,993,019, Emulsion, Massey University, 31 March 2015
- US Patent 8,987,244, Preventing and/or treating cardiovascular disease and/or associated heart failure, PhilERA (Professor Garth Cooper), 24 March 2015
Copyright © 2017 NDF Research